Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort
Metadatos
Mostrar el registro completo del ítemEditorial
Taylor & Francis
Materia
Colorectal cancer Escherichia coli Bacteroides fragilis Serology Prospective
Fecha
2021-04-20Referencia bibliográfica
Julia Butt... [et al.] (2021) Association of Pre-diagnostic Antibody Responses to Escherichia coli and Bacteroides fragilis Toxin Proteins with Colorectal Cancer in a European Cohort, Gut Microbes, 13:1, DOI: [10.1080/19490976.2021.1903825]
Patrocinador
European Commission (DG-SANCO); International Agency for Research on Cancer; Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Générale de l’Education Nationale, and Institut National de la Santé et de la Recherche Médicale (INSERM) (France); Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research (Germany); Hellenic Health Foundation (Greece); Sicilian Government, AIRE ONLUS Ragusa, AVIS Ragusa, Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); Nordic Centre of Excellence programme on Food, Nutrition and Health. (Norway); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucía, Asturias, Basque Country, Murcia, Navarra, and the Catalan Institute of Oncology (Barcelona), Spain; Swedish Cancer Society, Swedish Scientific Council, and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A19170, C570/A16491 and C8221/ A290170 to EPIC-Oxford), Medical Research Council (MR/ N003284/1 and MC-UU_12015/1 to EPIC-Norfolk, MR/ M012190/1 to EPIC-Oxford (UK); COST Action CA17118 supported by COST (European Cooperation in Science and Technology)Resumen
Experimental evidence has implicated genotoxic Escherichia coli (E. coli) and enterotoxigenic
Bacteroides fragilis (ETBF) in the development of colorectal cancer (CRC). However, evidence from
epidemiological studies is sparse. We therefore assessed the association of serological markers of
E. coli and ETBF exposure with odds of developing CRC in the European Prospective Investigation
into Nutrition and Cancer (EPIC) study.
Serum samples of incident CRC cases and matched controls (n = 442 pairs) were analyzed for
immunoglobulin (Ig) A and G antibody responses to seven E. coli proteins and two isoforms of the
ETBF toxin via multiplex serology. Multivariable-adjusted conditional logistic regression analyses were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association of
sero-positivity to E. coli and ETBF with CRC.
The IgA-positivity of any of the tested E. coli antigens was associated with higher odds of
developing CRC (OR: 1.42; 95% CI: 1.05–1.91). Dual-positivity for both IgA and IgG to E. coli and
ETBF was associated with >1.7-fold higher odds of developing CRC, with a significant association
only for IgG (OR: 1.75; 95% CI: 1.04, 2.94). This association was more pronounced when restricted to
the proximal colon cancers (OR: 2.62; 95% CI: 1.09, 6.29) compared to those of the distal colon (OR:
1.24; 95% CI: 0.51, 3.00) (pheterogeneity = 0.095). Sero-positivity to E. coli and ETBF was associated with
CRC development, suggesting that co-infection of these bacterial species may contribute to colorectal
carcinogenesis. These findings warrant further exploration in larger prospective studies and
within different population groups.